CRVO | CervoMed Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	14.00 - 15.38
52 Week Range	4.28 - 26.38
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	60,553
Average Volume	84,979
Shares Outstanding	8,253,740
Market Cap	118,441,169
Sector	Healthcare
Industry	Biotechnology
IPO Date	2008-05-23

Valuation
Profitability
Growth
Health
P/E Ratio	6.21
Forward P/E Ratio	N/A
EPS	2.31
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	CRVO

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

*Chart delayed

Analyzing fundamentals for CRVO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CRVO Fundamentals page.

Watching at CRVO technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on CRVO Technicals page.